|
|
| Petry,V.; Gagliato,D.M.; Leal,A.I.C.; Arai,R.J.; Longo,E.; Andrade,F.; Ricci,M.D.; Piato,J.R.; Barroso-Sousa,R.; Hoff,P.M.; Mano,M.S.. |
| Neoadjuvant chemotherapy has practical and theoretical advantages over adjuvant chemotherapy strategy in breast cancer (BC) management. Moreover, metronomic delivery has a more favorable toxicity profile. The present study examined the feasibility of neoadjuvant metronomic chemotherapy in two cohorts [HER2+ (TraQme) and HER2− (TAME)] of locally advanced BC. Twenty patients were prospectively enrolled (TraQme, n=9; TAME, n=11). Both cohorts received weekly paclitaxel at 100 mg/m2 during 8 weeks followed by weekly doxorubicin at 24 mg/m2 for 9 weeks in combination with oral cyclophosphamide at 100 mg/day (fixed dose). The HER2+ cohort received weekly trastuzumab. The study was interrupted because of safety issues. Thirty-six percent of patients in the TAME... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Breast cancer; Metronomic chemotherapy; HER2+. |
| Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000500479 |
| |
